2008 Highlights
January 2008
Receipt of the remaining funds of $17.7 million from the sale of shareholding in Domantis Ltd.
February 2008
Sale of animal health division.
 Major milestone achieved in project completion with partner CSL Limited – triggered a success-based payment by CSL.
March 2008
Commenced Phase II clinical trials in psoriasis for lead anti-TNF drug candidate ART621.
April 2008
Agreement with Kyowa Hakko Kirin (KHK) to co-develop a new anti-cancer drug for colorectal cancer (ART104). Upfront US$4 million  payment received with additional milestone payments of up to US$4 million.
June 2008
Entered collaborative agreement with  Greenovation to develop next generation anti-cancer antibodies.
Successful completion of second collaborative project with pharmaceutical partner CSL.
July 2008
New Sydney facility officially opened by the Hon Kim Carr, Federal Minister for Innovation, Industry, Science and Research.
 August 2008
Completed recruitment for Phase II psoriasis study for ART621.
September 2008
Filed Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for lead anti-inflammatory product ART621 in a rheumatoid arthritis indication.
October 2008
Successfully completed humanised and improved antibodies for Vegenics
(a subsidiary of Circadian Technologies Ltd.).
Share buy-back announced.
Gordon Black appointed as Non-executive Director.
 November 2008
ART621 able to commence clinical trials in rheumatoid arthritis under U.S. IND filing.
New Melbourne facilities officially opened
by the Hon Gavin Jennings, Victoria’s Minister for Innovation, Environment & Climate Change.
|
The partnership with KHK is particularly exciting. We are co-developing ART104 as a new anti-cancer drug for the large and important colorectal cancer market.
|
 |
 |
 |
|
